PET guided chemotherapy – monitoring metabolic effects of temozolomide chemotherapy in malignant gliomas and of long-term adjuvant chemotherapy in patients with glioblastoma

Aims: One general trend in oncology is to monitor biological effects of chemotherapy. [11C]methionine (MET)-PET may be a helpful tool to differentiate responders from non-responders and may provide valuable information for making treatment decisions, especially in non-responders. Therefore, MET-PET might have the potential to predict clinical outcome. A further focus of interest is the monitoring of metabolic effects in glioblastomas (GBM) when adjuvant temozolomide (TMZ) chemotherapy is been administered longer than 12 cycles; recent TMZ adjuvant chemotherapy recommendations suggest up to 6–12 cycles in the sta…